Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has
been shown to produce an objective response in patients with pretreated mBC. Oral …

Background Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth
factor receptor 2 (VEGFR-2). This study was conducted to assess the efficacy and safety of …

Objectives: This study evaluated the efficacy and safety of apatinib (an oral small-molecule
tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in …

Background Apatinib is a small molecule tyrosine kinase inhibitor (TKI) that is taken orally
and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This …

Simple Summary There are limited treatments for patients with HER2-negative breast
cancer, especially for patients with metastatic breast cancer. This study aimed to observe the …

Objectives The NCCN guidelines recommend that the addition of bevacizumab should be
considered in metastatic breast cancers in some circumstances, but there are no …

Introduction We performed this clinical trial to evaluate the efficacy and safety of apatinib and
oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer …

Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor
receptor 2. This study aimed to evaluate the efficacy and safety of apatinib in metastatic …

While therapies such as chemotherapy combined with immunotherapy, sacituzumab
govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression …

Locally advanced or metastatic disease accounts for the majority of breast cancer‑
associated cases of mortality. Treatment options for patients with locally advanced or …